Overview
Endocyte develops receptor-targeted therapeutics (or "smart drugs") that aim to take out bad cells without causing collateral damage. Receptor-targeted therapeutics are a precision alternative to non-targeted cancer drugs that can destroy healthy cells. Founded in 1996, Endocyte uses its drug guidance system to deliver drugs including small molecule cancer drugs and RNA-based therapies directly to cancerous cells, while leaving other cells unaffected.
...
Read More The firm has a pipeline of small molecule drug conjugates (SMDCs) in various stages of development. Its lead candidate, Vynfinit (vintafolide), is designed to treat ovarian cancer. Swiss pharma giant Novartis bought Endocyte for $2.1 billion in late 2018.
Read Less
Read More The firm has a pipeline of small molecule drug conjugates (SMDCs) in various stages of development. Its lead candidate, Vynfinit (vintafolide), is designed to treat ovarian cancer. Swiss pharma giant Novartis bought Endocyte for $2.1 billion in late 2018.
Read Less
Michael A Sherman
See more contacts
Scientific Research and Development Services
,
Professional, Scientific, and Technical Services
,
Biotechnical research, commercial
Accounting, Tax Preparation, Bookkeeping, and Payroll Services
,
Advertising, Public Relations, and Related Services
,
Architectural, Engineering, and Related Services
,
Computer Systems Design and Related Services
,
Legal Services
,
Management, Scientific, and Technical Consulting Services
,
Other Professional, Scientific, and Technical Services
,
Specialized Design Services
?
?
?
Actual
?
Actual
#
Actual
?
?
?
Contacts
Get in Touch with 5 Principals* and 38 Contacts
-
Michael A ShermanChief Executive Officer and President
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Data
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of ? (12 month period) in USD
Annual Revenue
?
USD
Modelled
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2017 | 2016 | 2015 |
|---|---|---|---|
| Net Operating Cash | -$34 | -$35 | -$32 |
| Net Investing Cash | $15 | $50 | $1 |
| Net Financing Cash | $6 | $0 | $1 |
| Net Change in Cash | -$13 | $16 | -$30 |
| Cash at Beginning of Period | $31 | $15 | $46 |
| Cash at End of Period | $19 | $31 | $15 |
| Capital Expenditure | -$13 | -$1 | -$0 |
| Assets (mil) | 2017 | 2016 | 2015 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $19 | $31 | $15 |
| Accounts Receivable | $ | $ | $ |
| Inventories | $ | $ | $ |
| Other Current Assets | $80 | $109 | $159 |
| Asset Summary | |||
| Total Current Assets | $99 | $140 | $175 |
| Tangible Fixed Assets | $2 | $3 | $3 |
| Intangible Assets | $ | $ | $ |
| Total Assets | $101 | $143 | $178 |
| Liabilities (mil) | 2017 | 2016 | 2015 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $0 | $1 | $1 |
| Short-Term Debt | $ | $ | $ |
| Other Current Liabilities | $4 | $4 | $5 |
| Liability Summary | |||
| Total Current Liabilities | $5 | $6 | $6 |
| Long-Term Debt | $ | $ | $ |
| Other Long-Term Liabilities | $ | $0 | $0 |
| Total Liabilities | $5 | $6 | $7 |
| Stakeholder's Equity (mil) | 2017 | 2016 | 2015 |
|---|---|---|---|
| Equity | |||
| Common Stock | $0 | $0 | $0 |
| Retained Earnings | -$309 | -$254 | -$210 |
| Equity Summary | |||
| Total Equity | $95 | $137 | $171 |
| Shares Outstanding | 48,203,529 | 42,377,522 | 41,784,692 |